Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$4.68 - $9.26 $23 - $46
5 Added 0.02%
20,561 $102,000
Q2 2023

Aug 14, 2023

BUY
$8.5 - $10.38 $127 - $155
15 Added 0.07%
20,556 $187,000
Q1 2023

May 15, 2023

SELL
$7.53 - $10.95 $6.37 Million - $9.27 Million
-846,238 Reduced 97.63%
20,541 $194,000
Q4 2022

Feb 14, 2023

SELL
$9.44 - $13.09 $4.89 Million - $6.78 Million
-517,807 Reduced 37.4%
866,779 $8.65 Million
Q3 2022

Nov 14, 2022

SELL
$8.14 - $12.25 $1.02 Million - $1.53 Million
-124,921 Reduced 8.28%
1,384,586 $16.5 Million
Q2 2022

Aug 15, 2022

SELL
$6.99 - $10.0 $1.17 Million - $1.68 Million
-168,019 Reduced 10.02%
1,509,507 $12.4 Million
Q1 2022

May 16, 2022

SELL
$7.26 - $10.7 $62,653 - $92,341
-8,630 Reduced 0.51%
1,677,526 $13.3 Million
Q4 2021

Feb 14, 2022

BUY
$8.8 - $16.0 $3.35 Million - $6.09 Million
380,780 Added 29.17%
1,686,156 $15.8 Million
Q3 2021

Nov 16, 2021

SELL
$15.23 - $21.72 $133,963 - $191,049
-8,796 Reduced 0.67%
1,305,376 $20.6 Million
Q2 2021

Aug 16, 2021

SELL
$17.8 - $23.5 $1.03 Million - $1.36 Million
-57,929 Reduced 4.22%
1,314,172 $28.4 Million
Q1 2021

May 17, 2021

SELL
$17.18 - $22.6 $2.29 Million - $3.01 Million
-133,131 Reduced 8.84%
1,372,101 $27.8 Million
Q4 2020

Feb 16, 2021

BUY
$11.5 - $17.96 $2.4 Million - $3.75 Million
208,820 Added 16.11%
1,505,232 $26.9 Million
Q3 2020

Nov 16, 2020

BUY
$10.62 - $13.12 $12,361 - $15,271
1,164 Added 0.09%
1,296,412 $15.1 Million
Q2 2020

Aug 14, 2020

BUY
$7.35 - $10.81 $2.31 Million - $3.39 Million
313,881 Added 31.98%
1,295,248 $12 Million
Q1 2020

May 14, 2020

BUY
$8.38 - $17.34 $8.22 Million - $17 Million
981,367 New
981,367 $10.2 Million

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $763M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.